Skip to main content
Fig. 3 | Multidisciplinary Respiratory Medicine

Fig. 3

From: Efficacy of recombinant human soluble thrombomodulin for the treatment of acute exacerbation of idiopathic pulmonary fibrosis: a single arm, non-randomized prospective clinical trial

Fig. 3

Kaplan–Meier distribution for the probability of survival without tracheal intubation. The solid line represents patients in the recombinant human soluble thrombomodulin (rhTM) group, and the dotted line represents patients in the untreated group. Survival was significantly better in the rhTM group than in the untreated group at 1 year (p = 0.04, log-rank test). rhTM: recombinant human soluble thrombomodulin

Back to article page

Multidisciplinary Respiratory Medicine

ISSN: 2049-6958

Contact us